source
- UK regulator advises stopping reimbursement for Amgen's lung cancer drug Lumakras for new patientsThe National Institute for Health and Care Excellence (NICE) in the United Kingdom released draft guidance recommending that government reimbursement for Amgen’s lung cancer therapy Lumakras be dis…
- FDA reprimands Lundbeck Seattle Biopharmaceuticals for inflated claims on Vyepti migraine webpagesThe U.S. Food and Drug Administration issued an untitled letter to Lundbeck Seattle Biopharmaceuticals criticizing two promotional webpages about its migraine treatment Vyepti. The agency said the…